Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Abstract
Beta blockers (timolol 0.5% ophthalmic solution) delivered topically to the eyes or sublingually have recently been reported in case series and small placebo controlled studies to be effective in some cases of acute migraine. Rapid systemic absorption to achieve therapeutic levels of beta blockers is extremely important in the treatment of acute migraine. Nasal delivered beta blockers have been shown to be absorbed as fast as intravenous administration and seem ideal for acute migraine treatment. A nasal delivered beta-blocker spray has not been available. In 2019, O'Brien Pharmacy prepared a compounded timolol nasal spray that is now available to authorized prescribers. The theoretical basis for using nasal beta blocker spray is presented and research on fast-acting beta-blocker solutions for acute migraine is reviewed.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.